Free tool
FAERS Monitor: Duavee
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022247 or its brand name (Duavee, Bazedoxifene Acetate, Estrogens, Conjugated). Reports on generic versions are filed under their own applications.
Reports
938
Serious
207
22% of reports
Hospitalization
34
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective141
- hot flush78
- nausea42
- muscle spasms41
- off label use39
- weight increased35
- feeling abnormal33
- headache33
- dizziness31
- insomnia31
- pain31
- therapeutic response unexpected25
- arthralgia24
- pain in extremity23
- drug effect incomplete22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 117 |
| 2015 | 260 |
| 2016 | 101 |
| 2017 | 72 |
| 2018 | 58 |
| 2019 | 58 |
| 2020 | 159 |
| 2021 | 23 |
| 2022 | 13 |
| 2023 | 20 |
| 2024 | 29 |
| 2025 | 20 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,221 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hot flushSignal | 78 | 23.2 | 18.8 | 1,641 |
| drug effect incompleteSignal | 22 | 13.6 | 9.0 | 244 |
| therapeutic response unexpectedSignal | 25 | 12.5 | 8.5 | 254 |
| muscle spasmsSignal | 41 | 5.0 | 3.7 | 129 |
| weight increasedSignal | 35 | 3.5 | 2.5 | 61 |
| feeling abnormalSignal | 33 | 3.1 | 2.2 | 45 |
| insomniaSignal | 31 | 2.6 | 1.8 | 30 |
| drug ineffectiveSignal | 141 | 2.4 | 2.1 | 121 |
| pain in extremity | 23 | 1.8 | 1.2 | 7 |
| dizziness | 31 | 1.4 | 1.0 | 3 |
| arthralgia | 24 | 1.3 | 0.9 | 1 |
| nausea | 42 | 1.2 | 0.9 | 1 |
| headache | 33 | 1.2 | 0.8 | 1 |
| pain | 31 | 1.1 | 0.8 | 0 |
| off label use | 39 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.